Study Summary
This trial is testing whether a combination of Vancomycin and Tobramycin powders is better than just Vancomycin powder at reducing post-fixation infections of tibial plateau and tibial pilon fractures.
- Post-operative Surgical Site Infections
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: within 365 days of definitive fracture fixation surgery
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Control
1 of 2
Treatment
1 of 2
Active Control
Experimental Treatment
1900 Total Participants · 2 Treatment Groups
Primary Treatment: Treatment group · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 80 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are participants needed for this research project?
"This trial, which is currently seeking patients, was first posted on May 11, 2021 and was most recently updated on July 27, 2022." - Anonymous Online Contributor
How can I sign up for the chance to be in this clinical trial?
"This study is looking for 1900 individuals that have had surgery for a wound infection and meet the following age, injury, and treatment criteria: 18-80 years old, tibia fracture with ipsilateral leg compartment syndrome and fasciotomy wounds that were initially treated with an external fixation, any open type I, II, or IIIA fracture, regardless of timing of definitive treatment." - Anonymous Online Contributor
Our target age-group for this experiment are those 35 years or older - are we still looking for test subjects in this age-range?
"The parameters for inclusion in this trial state that patients must be aged 18-80. There are 210 other trials for patients that are minors and 663 for elderly patients." - Anonymous Online Contributor
Are there any dangers associated with the use of this medication?
"Safety for the treatment group was estimated to be a 3. This is based off the fact that this is a phase 3 trial, which means that there is some data supporting efficacy as well as multiple rounds of data that support safety." - Anonymous Online Contributor